Affimed is rethinking development of its bispecific innate cell engager after getting a look at phase 1/2a monotherapy data. The biotech saw two partial responses in 15 patients, resulting in data that fell short of the continuation criteria but offered enough encouragement for it to plot more combination work.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,